You are here: Industry Insights > RGLS4326

News List

First Patient Dosed in RGLS4326 Trial for Autosomal Dominant Polycystic Kidney Disease americanpharmaceuticalreview
October 22, 2020
Regulus Therapeutics announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD.
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) prnewswire
October 16, 2020
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD.
Regulus Therapeutics Reinitiates RGLS4326 Study for ADPKD Treatment americanpharmaceuticalreview
March 10, 2020
Regulus Therapeutics has initiated dosing of the second cohort of its Phase 1 multiple ascending dose clinical trial (the "MAD study") of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).